網頁STELARA Ô是一種免疫抑制劑，因此可能會升高發生惡性腫瘤的風險。 在臨床研究中即曾有接受 STELARA Ô治療之受試者發生惡性腫瘤的報告 [ 參見不良反應 (6.1)] 。 齧齒類動物模型的研究顯示，抑制 IL-12/IL-23p40 會升高發生惡性腫瘤的風險 [ 參見非臨床毒物學 (13)] 。 目前尚未曾針對有惡性腫瘤病史或患有已知之惡性腫瘤的患者評估過使用 STELARA Ô治 … 網頁2024年3月4日 · SPRING HOUSE, Pa., March 4, 2024 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA ® (ustekinumab)...
J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector
網頁2024年4月14日 · J&J’s Pharma segment is expected to have contributed to the top line led by increased penetration and market share gains of key products such as Darzalex and Stelara. Regarding Stelara, while J&J expects Stelara volumes to increase till the loss of exclusivity in late 2024, the growth might have been hurt by pricing pressure as well as … 網頁2024年8月13日 · Stelara是靶向白细胞介素12（IL-12）和白细胞介素23（IL-23）单抗。 Stelara能够通过与IL-12和IL-23所共有的p40亚单位相结合，阻止其与细胞表面的受体IL-12 β1相结合，来抑制这2种前炎性细胞因子。 IL-12和IL-23是2种天然存在的蛋白质，被认为在免疫介导的炎症性疾病中发挥了关键作用，包括斑块型银屑病、银屑病关节炎、克罗恩病等 … intel founder andy grove
Help Your Patients Start and Stay on STELARA® Janssen …
Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23. Ustekinumab is approved to treat Crohn's … 查看更多內容 Ustekinumab is used to treat psoriasis. This includes psoriatic arthritis when it affects the skin. It is indicated for the treatment of adult and adolescent patients (12 years and older) with moderate to severe 查看更多內容 As of January 2007 , there were five NIH-listed research studies involving CNTO 1275 on a multinational basis, including three Phase II and two Phase III trials. Three studies … 查看更多內容 • "Ustekinumab". Drug Information Portal. U.S. National Library of Medicine. 查看更多內容 According to information provided by Centocor, maker of one medication based on ustekinumab, their version of ustekinumab is associated with several types of serious … 查看更多內容 Ustekinumab is designed to interfere with the triggering of the body's inflammatory response through the suppression of certain cytokines. Specifically, it blocks interleukin 查看更多內容 Since 2009, ustekinumab is approved in Canada, the European Union, and the United States to treat moderate to severe plaque psoriasis. … 查看更多內容 網頁Stelara是强生进军自身免疫性疾病领域的一款核心产品，该药在2024年创下了63.61亿美元的销售额，较2024年增长幅度达23.4%。 今年1月，国际顶级期刊《自然》（Nature）上发 … 網頁for STELARA injektionsvæske, opløsning (hætteglas) og injektionsvæske, opløsning i fyldt injektionssprøjte for oplysninger om dosering af det efterfølgende subkutane regime. Ældre (≥65år) Dosisjustering hos ældre patienter er ikke nødvendig (se pkt.4.4). intel foundation president